Fuss und Sprunggelenk最新文献_第2页

Einladung zur Mitgliederversammlung der Deutschen Assoziation für Fuß und Sprunggelenk e.V.

Fuss und Sprunggelenk Pub Date : 2025-03-01 DOI: 10.1016/j.fuspru.2025.02.001

引用次数: 0

Kongresskalender

Fuss und Sprunggelenk Pub Date : 2025-03-01 DOI: 10.1016/S1619-9987(25)00020-0

引用次数: 0

Knochenmarködem – Ätiologie und Behandlung

Fuss und Sprunggelenk Pub Date : 2025-03-01 DOI: 10.1016/j.fuspru.2025.01.004

F.P. Gaube , C. Behzadi , W. Böcker , H. Polzer , S.F. Baumbach

{"title":"Knochenmarködem – Ätiologie und Behandlung","authors":"F.P. Gaube , C. Behzadi , W. Böcker , H. Polzer , S.F. Baumbach","doi":"10.1016/j.fuspru.2025.01.004","DOIUrl":"10.1016/j.fuspru.2025.01.004","url":null,"abstract":"<div><div>Over the last decades, there has been a significant increase in the diagnosis of „bone marrow edema“ (BME). BME is primarily a radiological-descriptive term. It can be caused by a variety of physiological and pathophysiological processes. This narrative review aims to present a standardized diagnostic algorithm and summarize the existing evidence on adjunctive therapies.</div><div>The diagnostic algorithm is based on a sequential diagnostic approach, which includes MRI, X-ray/CT, basic laboratory tests, a detailed endocrinological laboratory workup, and DXA. This sequential process addresses traumatic, inflammatory, septic, mechanical/degenerative, ischemic/neurogenic, neoplastic, and metabolic causes of BME. Only when no specific cause has been identified, the BME should be classified as a bone marrow edema syndrome (BMES).</div><div>The cornerstone of BME therapy is identifying and treating the underlying pathology. Only by addressing the cause long-term recovery can be achieved. In addition to treating the primary disease—or in cases of isolated BMES—adjunctive conservative therapies (e.g., NSAIDs ± immobilization ± partial weight-bearing, shockwave therapy, pulsed electromagnetic fields) or pharmacological treatments (e.g., bisphosphonates or iloprost) may be considered. All pharmacological treatments are off-label and therefore require an informed consent. According to the authors, surgical treatment is not part of BME Management.</div></div>","PeriodicalId":39776,"journal":{"name":"Fuss und Sprunggelenk","volume":"23 1","pages":"Pages 2-14"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subchondral bone degeneration and pathology 3-15 years following ankle sprain injury in adolescent sport

Fuss und Sprunggelenk Pub Date : 2025-03-01 DOI: 10.1016/j.fuspru.2025.01.001

M. Jordan

引用次数: 0

Allogenic cancellous bone versus injectable bone substitute for endoscopic treatment of simple bone cyst and intraosseous lipoma of the calcaneus

Fuss und Sprunggelenk Pub Date : 2024-12-01 DOI: 10.1016/j.fuspru.2024.07.024

A. Toepfer

引用次数: 0

Nicht-invasive Kompartmendruckmessung von Patient:innnen mit dem Risiko eines akuten Kompartmentsyndroms nach Extremitätenverletzung mit dem CPMX1

Fuss und Sprunggelenk Pub Date : 2024-12-01 DOI: 10.1016/j.fuspru.2024.07.057

T. Gehlen, J.W. Kim, C. Eder, J. Löchel, U. Stöckle